Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Sumitomo grants Maruishi rights to FAAH inhibitor

October 6, 2017 6:44 PM UTC

Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) granted Maruishi Pharmaceutical Co. Ltd. (Osaka, Japan) exclusive development and commercialization rights to a preclinical fatty acid amide hydrolase (FAAH) inhibitor. The compound is testing in the U.S. and Japan to treat nausea and vomiting. Sumitomo Dainippon will receive an upfront payment and is eligible for milestones and royalties...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article